Hoth’s GDNF Outperforms Wegovy and Ozempic While GLP-1 Market Hits $137.4B by 2030
Hoth’s GDNF study outperformed Novo Nordisk’s Wegovy and Ozempic in weight stabilization, glucose tolerance, liver weight reduction and adipose tissue control. The global GLP-1 receptor agonist market is projected to grow from $51.9 billion in 2024 to $137.4 billion by 2030, with China expanding at a 23.4% CAGR.
1. Hoth Therapeutics' GDNF Study Challenges Ozempic and Wegovy
Hoth’s preclinical glial cell-derived neurotrophic factor (GDNF) program demonstrated superior performance to Novo Nordisk’s semaglutide-based products in weight stabilization, glucose tolerance, liver weight reduction and adipose tissue control. These results could signal increased competition in obesity and metabolic-associated liver disease markets.
2. GLP-1 Receptor Agonist Market Forecast
Industry projections estimate GLP-1 receptor agonist sales rising from $51.9 billion in 2024 to $137.4 billion by 2030, driven by expanding indications into NAFLD, NASH, cardiovascular and neurodegenerative disorders. China’s market is expected to grow at a 23.4% CAGR, presenting significant growth opportunities for Novo Nordisk’s Ozempic franchise.